Sponsorships
Alnylam Pharmaceuticals' Sponsorships fund educational and scientific initiatives advancing research and awareness in ATTR amyloidosis, AHP, and PH1.
Funder: Alnylam Pharmaceuticals
Due Dates: Rolling (apply at least 45 days before event/program start)
Funding Amounts: No set range; determined during review and agreement—varies by project/event.
Summary: Supports educational events and initiatives in ATTR amyloidosis, AHP, and PH1 that provide tangible benefits to Alnylam.
Key Information: As of September 1, 2026, sponsorship applications are no longer submitted via the portal—email sponsorships@alnylam.com to apply.
Description
Alnylam Pharmaceuticals offers sponsorship funding to support innovative, high-quality initiatives that enhance education and improve patient health in the areas of transthyretin-mediated amyloidosis (ATTR amyloidosis), acute hepatic porphyria (AHP), and primary hyperoxaluria type 1 (PH1). Eligible organizations can propose projects or events—such as educational conferences, patient or caregiver workshops, or scientific meetings—that educate patients, caregivers, scientists, or healthcare professionals and provide a tangible benefit to Alnylam (e.g., recognition, exhibit space). Supported initiatives should focus on disease awareness, early diagnosis, sharing best practices, or addressing unmet needs relevant to Alnylam’s therapeutic interests.
